NDFOS Co. Ltd (238090) - Total Liabilities

Latest as of September 2025: ₩14.82 Billion KRW ≈ $10.04 Million USD

Based on the latest financial reports, NDFOS Co. Ltd (238090) has total liabilities worth ₩14.82 Billion KRW (≈ $10.04 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of NDFOS Co. Ltd to assess how effectively this company generates cash.

NDFOS Co. Ltd - Total Liabilities Trend (2014–2024)

This chart illustrates how NDFOS Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of NDFOS Co. Ltd to evaluate the company's liquid asset resilience ratio.

NDFOS Co. Ltd Competitors by Total Liabilities

The table below lists competitors of NDFOS Co. Ltd ranked by their total liabilities.

Company Country Total Liabilities
CHUNGDAHM Learning Inc
KQ:096240
Korea ₩129.42 Billion
Vietnam National Seed Group JSC
VN:NSC
Vietnam ₫959.87 Billion
IFirma SA
WAR:IFI
Poland zł10.29 Million
Spectris PLC
LSE:SXS
UK GBX1.14 Billion
Demco Public Company Limited
BK:DEMCO
Thailand ฿2.50 Billion
Sentry Select Primary Metals Corp
TO:PME
Canada CA$179.00K
JHM Consolidation Bhd
KLSE:0127
Malaysia RM189.32 Million
Batm Advanced Communications Ltd
TA:BVC
Israel ILA52.24 Million

Liability Composition Analysis (2014–2024)

This chart breaks down NDFOS Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NDFOS Co. Ltd (238090) market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.96 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.15 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.13 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how NDFOS Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for NDFOS Co. Ltd (2014–2024)

The table below shows the annual total liabilities of NDFOS Co. Ltd from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 ₩15.70 Billion
≈ $10.64 Million
-5.75%
2023-12-31 ₩16.66 Billion
≈ $11.29 Million
-51.77%
2022-12-31 ₩34.55 Billion
≈ $23.41 Million
-50.44%
2021-12-31 ₩69.71 Billion
≈ $47.24 Million
+67.85%
2020-12-31 ₩41.53 Billion
≈ $28.15 Million
-47.23%
2019-12-31 ₩78.70 Billion
≈ $53.34 Million
+71.88%
2018-12-31 ₩45.79 Billion
≈ $31.03 Million
+275.02%
2017-12-31 ₩12.21 Billion
≈ $8.27 Million
+47.33%
2016-12-31 ₩8.29 Billion
≈ $5.62 Million
-20.84%
2015-12-31 ₩10.47 Billion
≈ $7.09 Million
-23.81%
2014-12-31 ₩13.74 Billion
≈ $9.31 Million
--

About NDFOS Co. Ltd

KQ:238090 Korea Specialty Chemicals
Market Cap
$51.06 Million
₩75.34 Billion KRW
Market Cap Rank
#21800 Global
#1424 in Korea
Share Price
₩3310.00
Change (1 day)
-1.49%
52-Week Range
₩1549.00 - ₩3950.00
All Time High
₩24250.00
About

NDFOS Co., Ltd. operates as a tape and film company in South Korea. The company offers adhesive tapes, such as waterproof tapes, light-shielding tapes, heat reaction tapes, battery fixing tapes, thin film tapes, convergence type functional tapes, and heat radiation tapes; functional films, including automobiles, industries, and everyday life. It also develops ARS and STR, anticancer drugs for can… Read more